In several cases, targeting various AML-associated antigens (such as FLT3 [130], CD123 [131], CD33 [132], CLL-1 [133], and GRP78 [134]) using multiple CARs may be necessary because certain tumor-associated antigens (TAAs) may not be expressed on all leukemia cells. Here, CD33 is linked to acute myeloid leukemia.